¿ Is seropositivity in patients with rheumatoid arthritis treated with adalimumab a factor to develop anti-adalimumab antibodies?
AMD Perilla, GM Vásquez, MX Rojas - Revista Colombiana de …, 2019 - Elsevier
Objective To determine whether seropositivity in rheumatoid arthritis patients treated with
adalimumab (ADL) is associated with the presence of anti-adalimumab (anti-ADL) …
adalimumab (ADL) is associated with the presence of anti-adalimumab (anti-ADL) …
¿ Es la seropositividad en pacientes con artritis reumatoide tratados con adalimumab un factor para desarrollar anticuerpos anti-adalimumab?
AMD Perilla, GM Vásquez, MX Rojas - Revista Colombiana de …, 2019 - Elsevier
Objetivo Determinar si la seropositividad en pacientes con artritis reumatoide tratados con
adalimumab (ADL), se asocia a la presencia de anticuerpos anti-adalimumab (anti-ADL) …
adalimumab (ADL), se asocia a la presencia de anticuerpos anti-adalimumab (anti-ADL) …
Immunoregulatory Role of Interleukin-37 in Rheumatoid Arthritis; Relation to Disease Activity and Joint Destruction
S DOAA, B DALIA, M HALA… - The Medical Journal of …, 2018 - mjcu.journals.ekb.eg
AbstractBackground: The Interleukin (IL)-37 is a member of IL-1 cytokines and reported to
down-regulate inflammation as a natural suppressor of innate immune responses. We …
down-regulate inflammation as a natural suppressor of innate immune responses. We …
[HTML][HTML] Advances in RA, PsO, PsA, and Related Disorders
AM Incassati, D Fernandez - medpagetoday.com
Rheumatoid arthritis (RA) is a chronic, pathological condition caused by systemic
inflammation. Rampant activation and infiltration of immune cells into the joints often leads to …
inflammation. Rampant activation and infiltration of immune cells into the joints often leads to …
[HTML][HTML] Towards Precision Rheumatology?
R Paganelli, E Celletti - Journal of Arthritis Research and …, 2018 - mail.oap-lifescience.org
The possibility of tailoring treatment on specific characteristics of patients–ie personalized
medicine–has received attention in the field of rheumatic diseases since biological DMARDs …
medicine–has received attention in the field of rheumatic diseases since biological DMARDs …
[PDF][PDF] Limfocyty B
M Massalska - REUMATOLOGÓW - open.icm.edu.pl
[78] Podstawy immunologii dla reumatologów warianty łańcuchów lekkich: κ (kappa) i λ
(lambda). W obrębie tej samej klasy nieznaczne różnice w budowie łańcuchów ciężkich …
(lambda). W obrębie tej samej klasy nieznaczne różnice w budowie łańcuchów ciężkich …
AB0224 Simulation for choice of bdmards and tsdmards in order to success for three-year survival in rheumatoid arthritis treatment
I Yoshii - 2017 - ard.bmj.com
Background In rheumatoid arthritis (RA) treatment, bDMARDs and tsDMARDs (BIO) perform
tremendous disease activity control, however, its effectiveness is uncertain and unstable …
tremendous disease activity control, however, its effectiveness is uncertain and unstable …
AB0221 Impact of small to medium dose of prednisolone on bone mineral density among early rheumatoid arthritis patients
Background Recent randomized trials in rheumatoid arthritis (RA) using low to medium dose
of corticosteroid showed that bone mineral density (BMD) loss over 2 years was not …
of corticosteroid showed that bone mineral density (BMD) loss over 2 years was not …
AB0223 Prognostic factors for radiographic damage in patients with seronegative rheumatoid arthritis
HY Lee, EJ Park, WS Jeong, J Kim - 2017 - ard.bmj.com
Background Long since it have been suggested that seronegative rheumatoid arthritis (RA)
represents a clinical entity quite distinct from that of seropositive RA. However, analytical …
represents a clinical entity quite distinct from that of seropositive RA. However, analytical …
Seronegative Rheumatoid Arthritis: A Case Control Study
M Antonelli, I Cobb, S Ballou - Journal of Autoimmune …, 2015 - synergypublishers.com
Background: Seronegative Rheumatoid Arthritis (RA) is a disorder associated with
considerable diagnostic, prognostic and therapeutic uncertainty for many clinicians …
considerable diagnostic, prognostic and therapeutic uncertainty for many clinicians …